(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Look at Medical caretaker Compensations Across Various Clinics - 2Everything you should know before booking a trip to Spain
- 3Before trips to Mars, we need better protection from cosmic rays
- 4Elite Execution Wall televisions for Film Darlings
- 5Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder
- FDA updates risk classification for voluntary shredded cheese recall
- The Ascent of Rousing Pioneers Who Formed History
- Novo Nordisk gears up for December Ozempic launch in India, sources say
- Israel scales back use of top missile interceptors as Iran barrages persist
- Germany and trade unions kick off tough public-sector wage talks
- German hauliers warn soaring energy prices may soon impact consumers
- Top Breakfast Food: What's Your Morning Enjoyment?
- The Meaning of Breaking the Pen's Nib in Death penalties
- A quick recap of 'Stranger Things' Seasons 1-4, plus key episodes to rewatch before Volume 1 of the final season drops
